関連レポート

肝細胞増殖因子（HGF）の世界市場：2034年予測

出版元：Transparency Market Research  出版元について

発行年：2024年6月

定価：Single User License $5795 Multi User License $8795 Corporate User License $11795

ご請求は円換算（お見積り日TTSレート）となります。

ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。

納品形態：PDF by Email

当調査レポートは英文 142ページになります。

商品コード：TMR292

当レポートは発行年月に関わらず、受注の都度、最新情報にアップデートしてお届けいたします。ご希望情報の追加等もご相談可能です。

レポート紹介

線維芽細胞増殖因子の世界市場規模は2023年で2億7070万ドル、2034年に6億4030万ドル、市場の平均年成長率は8.1%で増大する予想です。

当レポートでは、線維芽細胞増殖因子の市場予測-2034年、各種セグメント別市場分析(製品タイプ別、適応疾患別、国地域別、等)、パイプライン分析、COVID-19の影響分析、主要企業プロフィールなどの情報を盛り込み、概略以下の構成でお届けいたします。

【レポート構成概要】
■線維芽細胞増殖因子の世界市場予測2020-2034年
・市場規模(US$)

■製品タイプ別、市場-2034年
組換え型線維芽細胞増殖因子（FGF）
精製線維芽細胞増殖因子（FGF）
内因性線維芽細胞増殖因子（FGF）
※(市場規模US$)

■適応疾患別、市場-2034年
腫瘍学
血液学
創傷治癒
皮膚科学
心血管疾患
その他（糖尿病など）
※(市場規模US$)

■用途別、市場-2034年
細胞培養
研究
治療
※(市場規模US$)

■エンドユーザー別、市場-2034年
製薬会社/バイオテクノロジー企業
CMO（医薬品製造受託機関）/CDMO（医薬品開発製造受託機関）
研究センター/学術機関
※(市場規模US$)

■主要国地域別市場-2034年
北米
・米国、カナダ
欧州
・ドイツ、英国、フランス
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・オーストラリア/ニュージーランド
・その他アジア太平洋
中南米
・ブラジル、メキシコ
・その他中南米
中東アフリカ
・GCC諸国、南アフリカ
・その他中東アフリカ
※地域別に各種セグメント別の細分化データ掲載、詳細は目次参照

■市場分析
市場ダイナミクス（促進要因、障壁、機会）
パイプライン分析
COVID-19の影響分析
競合状況
市場シェア分析

■線維芽細胞増殖因子の主要企業プロフィール動向
Thermo Fisher Scientific
Sigma-Aldrich
PeproTech
R&D Systems
Abcam Limited
Cell Signalling Technology, Inc.
Novus Biologicals
（全142頁）

Table of Contents (英文詳細目次）

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fibroblast growth factors (FGFs) Market

4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, 2020-2034

5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2020-2034
6.3.1. Recombinant Fibroblast Growth Factor (FGF)
6.3.2. Purified Fibroblast Growth Factor (FGF)
6.3.3. Endogenous Fibroblast Growth Factor (FGF)
6.4. Market Attractiveness, by Product Type

7. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, by Disease Indication
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Indication, 2020-2034
7.3.1. Oncology
7.3.2. Hematology
7.3.3. Wound Healing
7.3.4. Dermatology
7.3.5. Cardiovascular Disease
7.3.6. Others (Diabetes, etc.)
7.4. Market Attractiveness, by Disease Indication

8. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, by Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2020-2034
8.3.1. Cell Culture
8.3.2. Research
8.3.3. Therapeutic
8.4. Market Attractiveness, by Application

9. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Pharmaceutical and Biotechnology Companies
9.3.2. CMOs & CDMOs
9.3.3. Research Centers & Academic Institutes
9.4. Market Attractiveness, by End-user

10. Global Fibroblast growth factors (FGFs) Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region

11. North America Fibroblast growth factors (FGFs) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2020-2034
11.2.1. Recombinant Fibroblast Growth Factor (FGF)
11.2.2. Purified Fibroblast Growth Factor (FGF)
11.2.3. Endogenous Fibroblast Growth Factor (FGF)
11.3. Market Attractiveness, by Product Type
11.4. Market Value Forecast, by Disease Indication, 2020-2034
11.4.1. Oncology
11.4.2. Hematology
11.4.3. Wound Healing
11.4.4. Dermatology
11.4.5. Cardiovascular Disease
11.4.6. Others (Diabetes, etc.)
11.5. Market Attractiveness, by Disease Indication
11.6. Market Value Forecast, by Application, 2020-2034
11.6.1. Cell Culture
11.6.2. Research
11.6.3. Therapeutic
11.7. Market Value Forecast, by End-user, 2020-2034
11.7.1. Pharmaceutical and Biotechnology Companies
11.7.2. CMOs & CDMOs
11.7.3. Research Centers & Academic Institutes
11.8. Market Attractiveness, by End-user
11.9. Market Value Forecast, by Country/Sub-region, 2020-2034
11.9.1. U.S.
11.9.2. Canada
11.10. Market Attractiveness Analysis
11.10.1. By Product Type
11.10.2. By Disease Indication
11.10.3. By Application
11.10.4. By End-user
11.10.5. By Country

12. Europe Fibroblast growth factors (FGFs) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2020-2034
12.2.1. Recombinant Fibroblast Growth Factor (FGF)
12.2.2. Purified Fibroblast Growth Factor (FGF)
12.2.3. Endogenous Fibroblast Growth Factor (FGF)
12.3. Market Attractiveness, by Product Type
12.4. Market Value Forecast, by Disease Indication, 2020-2034
12.4.1. Oncology
12.4.2. Hematology
12.4.3. Wound Healing
12.4.4. Dermatology
12.4.5. Cardiovascular Disease
12.4.6. Others (Diabetes, etc.)
12.5. Market Attractiveness, by Disease Indication
12.6. Market Value Forecast, by Application, 2020-2034
12.6.1. Cell Culture
12.6.2. Research
12.6.3. Therapeutic
12.7. Market Attractiveness, by Application
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Pharmaceutical and Biotechnology Companies
12.8.2. CMOs & CDMOs
12.8.3. Research Centers & Academic Institutes
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Product Type
12.11.2. By Disease Indication
12.11.3. By Application
12.11.4. By End-user
12.11.5. By Country/Sub-region

13. Asia Pacific Fibroblast growth factors (FGFs) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2020-2034
13.2.1. Recombinant Fibroblast Growth Factor (FGF)
13.2.2. Purified Fibroblast Growth Factor (FGF)
13.2.3. Endogenous Fibroblast Growth Factor (FGF)
13.3. Market Attractiveness, by Product Type
13.4. Market Value Forecast, by Disease Indication, 2020-2034
13.4.1. Oncology
13.4.2. Hematology
13.4.3. Wound Healing
13.4.4. Dermatology
13.4.5. Cardiovascular Disease
13.4.6. Others (Diabetes, etc.)
13.5. Market Attractiveness, by Disease Indication
13.6. Market Value Forecast, by Application, 2020-2034
13.6.1. Cell Culture
13.6.2. Research
13.6.3. Therapeutic
13.7. Market Attractiveness, by Application
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Pharmaceutical and Biotechnology Companies
13.8.2. CMOs & CDMOs
13.8.3. Research Centers & Academic Institutes
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Product Type
13.11.2. By Disease Indication
13.11.3. By Application
13.11.4. By End-user
13.11.5. By Country/Sub-region

14. Latin America Fibroblast growth factors (FGFs) Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2020-2034
14.2.1. Recombinant Fibroblast Growth Factor (FGF)
14.2.2. Purified Fibroblast Growth Factor (FGF)
14.2.3. Endogenous Fibroblast Growth Factor (FGF)
14.3. Market Attractiveness, by Product Type
14.4. Market Value Forecast, by Disease Indication, 2020-2034
14.4.1. Oncology
14.4.2. Hematology
14.4.3. Wound Healing
14.4.4. Dermatology
14.4.5. Cardiovascular Disease
14.4.6. Others (Diabetes, etc.)
14.5. Market Attractiveness, by Disease Indication
14.6. Market Value Forecast, by Application, 2020-2034
14.6.1. Cell Culture
14.6.2. Research
14.6.3. Therapeutic
14.7. Market Attractiveness, by Application
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Pharmaceutical and Biotechnology Companies
14.8.2. CMOs & CDMOs
14.8.3. Research Centers & Academic Institutes
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Product Type
14.11.2. By Disease Indication
14.11.3. By Application
14.11.4. By End-user
14.11.5. By Country/Sub-region

15. Middle East & Africa Fibroblast growth factors (FGFs) Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2020-2034
15.2.1. Recombinant Fibroblast Growth Factor (FGF)
15.2.2. Purified Fibroblast Growth Factor (FGF)
15.2.3. Endogenous Fibroblast Growth Factor (FGF)
15.3. Market Attractiveness, by Product Type
15.4. Market Value Forecast, by Disease Indication, 2020-2034
15.4.1. Oncology
15.4.2. Hematology
15.4.3. Wound Healing
15.4.4. Dermatology
15.4.5. Cardiovascular Disease
15.4.6. Others (Diabetes, etc.)
15.5. Market Attractiveness, by Disease Indication
15.6. Market Value Forecast, by Application, 2020-2034
15.6.1. Cell Culture
15.6.2. Research
15.6.3. Therapeutic
15.7. Market Attractiveness, by Application
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Pharmaceutical and Biotechnology Companies
15.8.2. CMOs & CDMOs
15.8.3. Research Centers & Academic Institutes
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Product Type
15.11.2. By Disease Indication
15.11.3. By Application
15.11.4. By End-user
15.11.5. By Country/Sub-region

16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Sigma-Aldrich
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. PeproTech
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. R&D Systems
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Abcam Limited
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Cell Signalling Technology, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Novus Biologicals
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview

List of Tables

Table 01: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 02: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 03: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 04: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 05: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Region, 2020-2034

Table 06: North America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Country, 2020-2034

Table 07: North America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 08: North America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 09: North America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 10: North America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 11: Europe Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 12: Europe Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 13: Europe Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 14: Europe Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 15: Europe Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 16: Asia Pacific Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 17: Asia Pacific Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 18: Asia Pacific Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 19: Asia Pacific Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 20: Asia Pacific Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 21: Latin America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 22: Latin America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 23: Latin America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 24: Latin America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 25: Latin America Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

Table 26: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034

Table 27: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Product Type, 2020-2034

Table 28: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Disease Indication, 2020-2034

Table 29: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by Application, 2020-2034

Table 30: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

Figure 01: Global Fibroblast growth factors (FGFs) Market Size (US$ Mn), by Region, 2023 and 2034

Figure 02: Global Fibroblast growth factors (FGFs) Market Revenue (US$ Mn), by Product Type, 2023

Figure 03: Global Fibroblast growth factors (FGFs) Market Value Share, by Product Type, 2023

Figure 04: Global Fibroblast growth factors (FGFs) Market Revenue (US$ Mn), by Disease Indication, 2023

Figure 05: Global Fibroblast growth factors (FGFs) Market Value Share, by Disease Indication, 2023

Figure 06: Global Fibroblast growth factors (FGFs) Market Revenue (US$ Mn), by Application, 2023

Figure 07: Global Fibroblast growth factors (FGFs) Market Value Share, by Application, 2023

Figure 08: Global Fibroblast growth factors (FGFs) Market Revenue (US$ Mn), by End-user, 2023

Figure 09: Global Fibroblast growth factors (FGFs) Market Value Share, by End-user, 2023

Figure 10: Global Fibroblast growth factors (FGFs) Market Value Share, by Region, 2023

Figure 11: Global Fibroblast growth factors (FGFs) Market Value (US$ Mn) Forecast, 2020-2034

Figure 12: Global Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 13: Global Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 14: Global Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 15: Global Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 16: Global Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 17: Global Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 18: Global Fibroblast growth factors (FGFs) Market Revenue (US$ Mn), by End-user, 2023

Figure 19: Global Fibroblast growth factors (FGFs) Market Value Share, by End-user, 2023

Figure 20: Global Fibroblast growth factors (FGFs) Market Value Share Analysis, by Region, 2023 and 2034

Figure 21: Global Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Region, 2024-2034

Figure 22: North America Fibroblast growth factors (FGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 23: North America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Country, 2024-2034

Figure 24: North America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Country, 2023 and 2034

Figure 25: North America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 26: North America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 27: North America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 28: North America Fibroblast growth factors (FGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 29: North America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 30: North America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 31: North America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 32: North America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 33: Europe Fibroblast growth factors (FGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 34: Europe Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 35: Europe Fibroblast growth factors (FGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 36: Europe Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 37: Europe Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 38: Europe Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 39: Europe Fibroblast growth factors (FGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 40: Europe Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 41: Europe Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 42: Europe Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 43: Europe Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 44: Asia Pacific Fibroblast growth factors (FGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 45: Asia Pacific Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 46: Asia Pacific Fibroblast growth factors (FGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 47: Asia Pacific Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 48: Asia Pacific Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 49: Asia Pacific Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 50: Asia Pacific Fibroblast growth factors (FGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 51: Asia Pacific Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 52: Asia Pacific Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 53: Asia Pacific Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 54: Asia Pacific Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by End-user, 2023-2034

Figure 55: Latin America Fibroblast growth factors (FGFs) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 56: Latin America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 57: Latin America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 58: Latin America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 59: Latin America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 60: Latin America Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 61: Latin America Fibroblast growth factors (FGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 62: Latin America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 63: Latin America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 64: Latin America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 65: Latin America Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by End-user, 2024-2034

Figure 66: Middle East & Africa Fibroblast growth factors (FGFs) Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034

Figure 67: Middle East & Africa Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

Figure 68: Middle East & Africa Fibroblast growth factors (FGFs) Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

Figure 69: Middle East & Africa Fibroblast growth factors (FGFs) Market Value Share Analysis, by Product Type, 2023 and 2034

Figure 70: Middle East & Africa Fibroblast growth factors (FGFs) Market Value Share Analysis, by Disease Indication, 2023 and 2034

Figure 71: Middle East & Africa Fibroblast growth factors (FGFs) Market Value Share Analysis, by Application, 2023 and 2034

Figure 72: Middle East & Africa Fibroblast growth factors (FGFs) Market Value Share Analysis, by End-user, 2023 and 2034

Figure 73: Middle East & Africa Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Product Type, 2024-2034

Figure 74: Middle East & Africa Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Disease Indication, 2024-2034

Figure 75: Middle East & Africa Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by Application, 2024-2034

Figure 76: Middle East & Africa Fibroblast growth factors (FGFs) Market Attractiveness Analysis, by End-user, 2024-2034

△ 一番上に戻る